Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/16/2010US7834055 Compositions and methods for the treatment of skin
11/16/2010US7834054 Hydroxamates as therapeutic agents
11/16/2010US7834053 2-[[3-(2-benzo[b]thiophen-5-yl-ethoxy)propyl](methyl)amino]-1-ethanol; antihypoxic agent; synergistic mixture with acetylcholine esterase inhibitor (Tacrine, Donepezil, Rivastigmine); neurodegenerative diseases, ischemic cerebral lesion, cerebral apoplexy, Alzheimer's disease, cognition activator
11/16/2010US7834052 TNF alpha inhibitors; inflammatory diseases such as rheumatoid arthritis, Crohn's disease, septic shock syndrome and atherosclerosis
11/16/2010US7834051 Cyclic amine compounds
11/16/2010US7834050 Small molecule insulin mimetics absent quinones
11/16/2010US7834049 Integrin expression inhibitor
11/16/2010US7834048 7-(sulfonamido-aryl substituted)-3-azabicyclo[3.2.0]heptane compounds; Parkinson's disease, schizophrenia, depression, anxiety, addiction, renal disorders, eating disorders
11/16/2010US7834047 Arylsulfonamides and uses related thereto
11/16/2010US7834046 Thiophene compounds
11/16/2010US7834044 Substituted-2-imidazoles
11/16/2010US7834043 Prevent reproduct of aids virus
11/16/2010US7834042 Angiotensin II receptor antagonists
11/16/2010US7834041 angiotensin II type 1 (AT1) receptor antagonist activity and neprilysin inhibition activity; aryl compounds with both tert-amide and another tert or sec-amide group
11/16/2010US7834040 Isoxazolic derivative to relieve neuropathic pain
11/16/2010US7834039 Oxadiazole compounds
11/16/2010US7834038 Methods for preparing nonpeptidic oligomers from amino acids
11/16/2010US7834037 5-lipoxygenase-activating protein (FLAP) inhibitors
11/16/2010US7834036 Fused-aromatic compounds having anti-diabetic activity
11/16/2010US7834035 Allosteric modulators of metabotropic glutamate receptors
11/16/2010US7834034 Benzothiophene derivatives
11/16/2010US7834033 administering a tumor necrosis factor inhibitor; angiogenesis inhibitor; treating inflammatory, and autoimmune diseases
11/16/2010US7834032 Piperidine derivatives
11/16/2010US7834031 18F, 11C, or deuterated fluoromethoxy-substituted 4-phenyl-4-benzoylaminomethylpiperindosulfonyl compounds for diagnostic imaging
11/16/2010US7834030 PPAR agonists; modulate lipid and/or carbohydrate metabolism in mammals; prevention and/or treatment of type-2 diabetes, atherosclerosis, cardiovascular disorders; 3-(2-Chloro-4-{1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-phenyl)-4H-[1,2,4]oxadiazol-5-one
11/16/2010US7834029 For therapy of cancer; treating prostate cancer with 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole; TGF-beta signal transduction inhibitors
11/16/2010US7834028 Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
11/16/2010US7834027 Gemifloxacin process and polymorphs
11/16/2010US7834026 histone deacetylase inhibitors; antiproliferative; antineoplastic; thioredoxin (TRX)-mediated diseases such as autoimmune, allergy, inflammatory diseases; and neurodegenerative diseases; N-(2-Aminophenyl)-6-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)nicotinamide; hydroxamic acid moiety
11/16/2010US7834025 Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
11/16/2010US7834024 Prevent transplant rejection; autoimmune diseases
11/16/2010US7834023 Antithrombotic activity ; 2-(5-chlorothiophen-2-yl)-2-(4-(6-ethyl-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)benzamido)acetic acid for example
11/16/2010US7834022 enzyme inhibitor for treating immune-related diseases, skin disorders, myeloid proliferative disorders, cancer; allograft rejection or graft versus host disease
11/16/2010US7834020 Crystal structure; antidepressants; anxiolytic agents; eating disorders; bipolar disorders; Alzheimer's disease; sleep disorders; psychiatric disorders; sexual dysfunctions; fibromyalgia
11/16/2010US7834019 3-(2-allyl-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-3-oxo-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-1-yl)-N,N-dimethylbenzamide; Weel kinase inhibitor; treatment of various cancers; composition with other anticancer agents
11/16/2010US7834018 Aminopyridine derivatives having aurora a selective inhibitory action
11/16/2010US7834017 Melanocortin receptor modulators; sexual disorders, obesity, cachexia, eating disorders; for example 1,4-bis(2-amino-3-p-tolyl-propionyl)-2-isobutyl-5-(4-(2-aminoethylamino)butyl)piperazine
11/16/2010US7834016 breast cancer, prostate cancer, and colon cancer; indole, indoline, indol-2-one, or benzimidazoline based compounds having arylamine groups, for example 1-(pyrid-4-ylamino)-4-(2-(indol-3-yl)ethylamino)benzene
11/16/2010US7834015 Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
11/16/2010US7834014 Parkinson's disease; [2-(7-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)-octahydro-pyrido[1,2-a]pyrazin-7-yl]-methanol;
11/16/2010US7834013 Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]cyclopropanecarboxylic acid; type II diabetes; G protein-coupled receptor 40 (GPR40) agonists
11/16/2010US7834012 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
11/16/2010US7834011 Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
11/16/2010US7834010 gastrointestinal disorders, urinary tract disorders such as hyperactive bladder, and cardiovascular disorders without side effects related to CNS activity; acid moiety makes drug unable to cross the blood-brain barrier; carboxy, phosphonic, sulfonic, or phosphoric acid derivative of piboserod (DDL-6001)
11/16/2010US7834009 treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent
11/16/2010US7834008 neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide
11/16/2010US7834007 Calcitonin gene-related peptide (CGRP); migraines; amido- and urea or carbamate functional compounds containing piperidine and one of indazolyl, benzotriazolyl, or benzooxazolin-2-one rings
11/16/2010US7834006 antidiabetics; lower blood glucose levels; compounds based on 1H,2H,3H,4H,5H,6H,7H,8H-pyrrolo[3,4-e][1,4]diazepin-6-one
11/16/2010US7834005 anticancer, antiviral, antibiotic use; new derivatives of anthramycin class of antitumor antibiotics
11/16/2010US7834004 N-sulfonyl heterocyclic ring such as piperazine connected via sulfonyl group to another fused heterocyclic ring such as benzothiophene or indoline; peroxisome proliferator-activated receptor (PPAR); obesity, diabetes, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome
11/16/2010US7834003 Use as miticide, insecticide, anthelmintic, nematocide; veterinary medicine, pest control; compounds are 1-trisubstituted phenyl-5-(2,3-dioxypropylamino)-4-thio(oxo)-3-substituted pyrazoles
11/16/2010US7834002 4-amino-5-cyanopyrimidine derivatives
11/16/2010US7834001 N-(10,10-Dioxo-10,11-dihydro-5-oxa-10-lambda*6*-thia-dibenzo[a.d]cycloheptene-8-carbonyl)-guanidine; tumor necrosis factor inhibitors; sodium-proton exchange inhibitors for treatment of organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy
11/16/2010US7834000 CGRP receptor antagonists
11/16/2010US7833999 histamine H3 receptor modulators; obesity, diabetes and central nervous system diseases such as vigilance and sleep disorders; e.g. (+)-2-(cyclohexylmethyl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl] -1,2,3 ,4-tetrahydroisoquinoline-7-sulfonamide
11/16/2010US7833998 cephalosporin sulfoxides or sulfones; carboxypeptidase E inhibitors; neurological disease, a behavioral disorder, or a cognitive disorder;
11/16/2010US7833997 Soluble 17-amino-analogs of geldanamycin in acid addition salt form; water solubility; anticancer agents; storage stability
11/16/2010US7833996 Composition and method for controlling rice water weevils
11/16/2010US7833995 Blood flow promoters for cauda equina tissues
11/16/2010US7833994 heating and hydrolyzing corn fiber slurry to achieve a residual corn fiber having a moisture content from about 30 to 80 weight percent solids; energy efficiency, no need for complete dry; dustless in a safe, nonexplosive environment
11/16/2010US7833993 Bisphosphate, bis-quaternary ammonium or bis-amine salt compounds that bind a Toll-like receptor; use desensitizing allergies, treating autoimmune diseases and inflammatory diseases, ischemia
11/16/2010US7833992 biological conjugates used for drug delivery; side effect reduction
11/16/2010US7833990 accelerating vascular endothelial repair with a low haemorrhage risk in the event of thrombotic injuries; promoting revascularization in ischemic tissues and vascular modelling in thrombotic injuries; produced by the marine bacterium Alteromonas
11/16/2010US7833988 Oncoprotein specific immunoglobulin for use as tool in tumor diagnosis and treatment; antitumor agents
11/16/2010US7833987 Small synthetic RNA, a method of preparing the same and uses thereof
11/16/2010US7833977 Use of L-carnitine for the treatment of cataract of non diabetic origin due to altered chaperone proteins by stabilizing the protein activity
11/16/2010US7833973 comprising ziconotide, methionine and hydromorphone for producing analgesia in a mammalian subject; reduces the side effects, no drug interactions
11/16/2010US7833965 Biocompatible liquid, biocompatible gas, and solid particles of a biocompatible polymer are mixed together to form a homogenous composition including a discontinuous gas phase with solid particles homogenously dispersed throughout a continuous liquid phase
11/16/2010US7833942 Methods for simplifying microbial nucleic acids by chemical modification of cytosines
11/16/2010US7833753 Mixture comprising sialinated erythropoietin (EPO) for use in generating stable, human, recombinant proteins that are modified post-translationally
11/16/2010US7833722 Ligands for G protein-coupled receptor protein and use thereof
11/16/2010US7833554 Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency
11/16/2010US7833551 biosynthesis inhibition via formaldehyde, glutaraldehyde, acrolein, quaternary amine compounds, cocodiamine, bronopol, 2-2-dibromo-3-nitrilo-propionamide; synergistic; cost efficiency
11/16/2010US7833550 suspending diketopiperazine microparticles with antihistamine (azelastine) to form suspension, forming drug-coated diketopiperazine microparticles by removing solvent therefrom; low dosage, targets nasal cavity, does not impart bitter taste, reduced drowsiness
11/16/2010US7833549 Drug delivery; controlling particle sizes
11/16/2010US7833547 Tablets, granules formed by compression
11/16/2010US7833546 Pharmaceutical dosage form and method for the production thereof
11/16/2010US7833545 Methods and devices for the sustained release of multiple drugs
11/16/2010US7833542 Method and composition for the treatment of scars
11/16/2010US7833538 using an immunostimulatory dinucleotide of formula CpG*, wherein C is a natural or non-natural pyrimidine nucleoside and G* is 7-deazaguanosine; for treating autoimmune disorders, such as autoimmune asthma; allergies
11/16/2010US7833187 Systems and methods for improving image-guided tissue ablation
11/16/2010CA2686429C Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
11/16/2010CA2622452C Hemodynamics improving agent
11/16/2010CA2532714C Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
11/16/2010CA2523216C Recombinant alphavirus vectors
11/16/2010CA2523158C Delayed release tablet with defined core geometry
11/16/2010CA2510655C Uses of adenosine a2a receptor antagonists
11/16/2010CA2487329C Process for the manufacture of quinoline derivatives
11/16/2010CA2479084C Vdac regulator
11/16/2010CA2477474C Cyclic n-substituted alpha imino carboxylic acids for selective inhibition of collagenase
11/16/2010CA2477109C System for transvaginal drug delivery
11/16/2010CA2471220C Novel alkansulfonamides as endothelin antagonists
11/16/2010CA2455621C Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders
11/16/2010CA2452114C Tgf-.beta. superfamily production/secretion promoter
11/16/2010CA2436846C Thioether substituted imidazoquinolines
11/16/2010CA2430897C Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders
11/16/2010CA2429205C Dermatological formulations
11/16/2010CA2427548C Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them
11/16/2010CA2416535C Non-sedating barbiturate compounds as neuroprotective agents
11/16/2010CA2415643C Pharmaceutical composition for oral use with improved absorption
1 ... 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 ... 7860